Evidence map›Paper›PMID 27195187›Full record

ReviewIntractable & rare diseases research2016

Granulomatosis with polyangiitis (Wegener's disease): An updated review of ocular disease manifestations.

Buraa Kubaisi, Khawla Abu Samra, C Stephen Foster

Open access · diamondAbstract readReview
In one paragraph

Review in Intractable & rare diseases research, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 1 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 1 synthesis or guideline pooled it, 136 citations in OpenAlex.

  1. Pooled it
  2. Ocular Manifestations at Diagnosis of Anti-Neutrophil Cytoplasmic Anti-body-Associated Vasculitis: Clinical İmplications from a Retrospective Cohort.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2026
    Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Violaceous Papules on Face.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Buraa KubaisiMassachusetts Eye Research and Surgery institution, Waltham, MA, USA; Ocular Immunology and Uveitis Foundation, Waltham, MA, USA.
Khawla Abu SamraMassachusetts Eye Research and Surgery institution, Waltham, MA, USA; Ocular Immunology and Uveitis Foundation, Waltham, MA, USA.
C Stephen FosterMassachusetts Eye Research and Surgery institution, Waltham, MA, USA; Ocular Immunology and Uveitis Foundation, Waltham, MA, USA; Harvard Medical School, Boston, MA, USA.
Ocular Immunology and Uveitis Foundation · USMassachusetts Eye Research and Surgery Institute · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Granulomatosis with polyangiitis (GPA) is a potentially lethal systemic disorder that is characterized by necrotizing vasculitis of small arteries and veins. The respiratory system is most commonly affected in limited forms of the disease, however upper and lower respiratory system, systemic vasculitis, and necrotizing glomerulonephritis are the characteristic components of the disease triad. The peak incidence is observed at 64-75 years of age, with a prevalence of 8-10 per million depending on geographic location. In this review we focus on the ocular manifestations of the disease which occur in nearly in one third of the patients. In addition we describe the neuro-ophthalmic complications which occur in up to half of cases. We also discuss the current systemic treatment options including corticosteroids, cyclophosphamide, azathioprine, and the available biologic response modifiers including rituximab. The disease remains difficult to diagnose due to the generalized symptomatic presentation of patients with GPA. As a result, several sets of diagnostic criteria have been developed which include clinical, serological, and histopathological findings to varying extents. Early diagnosis and multi-specialty collaboration among physicians is necessary to adequately manage the disease and the potential complications that may result from drugs used in the treatment of the disease. Despite recent advances, more research is necessary to prevent the high rates of mortality from the disease itself and from therapeutic side effects.

Indexed as

granulomaGranulomatosis with polyangiitisocular complicationsvasculitisWegener's

Identifiers

PMID27195187
PMCPMC4869584
OpenAlexW2322155217

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.